SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 2, 2010
Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 1.01 Entry into a Material Definitive Agreement.
On September 2, 2010, Revolutions Medical Corporation, a Nevada corporation (the “Company”), entered into a manufacturing agreement (the “Agreement”) with Medical Investment Group, LLC, a Massachusetts limited liability corporation (“MIG”). Pursuant to the terms of the Agreement, for a period of five years, MIG shall manufacture and deliver 5,000,000 RevVac 3ml safety syringes (the “Syringes”) per month for the benefit of the Company. As further consideration for entering into the Agreement, the Company promises to deliver: (i) 40,000 shares of the Company’s common stock, par value $0.001 per share, to MIG; (ii) $600,000 to MIG, such payment subject to the outlined schedule in Section 2 of the Agreement; and (iii) up to 1,000,000 shares or warrants to purchase shares of the Company’s common stock, to MIG, subject to the execution of a final logistics agreement by and between MIG and the Company.
The above description of the Agreement does not purport to be complete and is qualified in its entity by reference to such Agreement, which the Company has filed as Exhibit 10.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.